Jung Hun Kang

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Woo Kyun Bae · 2 shared papers, 2021 · strength 0.21
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
   • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
2. In Gyu Hwang · 3 shared papers, 2012–2021 · strength 0.21
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
   • Paper Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study. DOI 10.1186/s40880-018-0304-1↗
   • Paper A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. DOI 10.1007/s10637-012-9792-z↗
3. Jung Hoon Kim · 2 shared papers, 2018–2021 · strength 0.18
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
   • Paper Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study. DOI 10.1186/s40880-018-0304-1↗
4. Se‐Il Go · 2 shared papers, 2012–2021 · strength 0.14
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
   • Paper A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. DOI 10.1007/s10637-012-9792-z↗
5. Dae Young Zang · 1 shared paper, 2021 · strength 0.11
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
6. Jun Ho Ji · 1 shared paper, 2021 · strength 0.11
   • Paper Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients:… DOI 10.1016/j.ejca.2021.08.002↗
7. H.S. Park · 1 shared paper, 2021 · strength 0.10
   • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
8. Choong‐kun Lee · 1 shared paper, 2021 · strength 0.10
   • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
9. Hye Jin Choi · 1 shared paper, 2021 · strength 0.10
   • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
10. Sung Hee Lim · 1 shared paper, 2021 · strength 0.10
    • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
11. Joon Oh Park · 1 shared paper, 2021 · strength 0.10
    • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗
12. Changhoon Yoo · 1 shared paper, 2021 · strength 0.10
    • Paper Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with m… DOI 10.1016/j.esmoop.2021.100049↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.